What 6 Analyst Ratings Have To Say About Black Diamond Therapeutic
Portfolio Pulse from Benzinga Insights
In the last quarter, Black Diamond Therapeutic (NASDAQ:BDTX) received 2 bullish, 3 somewhat bullish, and 1 indifferent rating from analysts. The average price target is $9.0, a significant increase from the previous target of $2.5, implying an upside compared to the current price of $3.55.
September 12, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a bullish sentiment towards Black Diamond Therapeutic, with an average price target of $9.0, indicating a potential upside.
The bullish and somewhat bullish ratings from analysts indicate a positive sentiment towards the stock. The significant increase in the average price target also suggests a potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100